Literature DB >> 25620056

Changes in cholesterol homeostasis and acute phase response link pulmonary exposure to multi-walled carbon nanotubes to risk of cardiovascular disease.

Sarah S Poulsen1, Anne T Saber2, Alicja Mortensen3, Józef Szarek4, Dongmei Wu5, Andrew Williams6, Ole Andersen7, Nicklas R Jacobsen8, Carole L Yauk9, Håkan Wallin10, Sabina Halappanavar11, Ulla Vogel12.   

Abstract

Adverse lung effects following pulmonary exposure to multi-walled carbon nanotubes (MWCNTs) are well documented in rodents. However, systemic effects are less understood. Epidemiological studies have shown increased cardiovascular disease risk after pulmonary exposure to airborne particles, which has led to concerns that inhalation exposure to MWCNTs might pose similar risks. We analyzed parameters related to cardiovascular disease, including plasma acute phase response (APR) proteins and plasma lipids, in female C57BL/6 mice exposed to a single intratracheal instillation of 0, 18, 54 or 162μg/mouse of small, entangled (CNTSmall, 0.8±0.1μm long) or large, thick MWCNTs (CNTLarge, 4±0.4μm long). Liver tissues and plasma were harvested 1, 3 and 28days post-exposure. In addition, global hepatic gene expression, hepatic cholesterol content and liver histology were used to assess hepatic effects. The two MWCNTs induced similar systemic responses despite their different physicochemical properties. APR proteins SAA3 and haptoglobin, plasma total cholesterol and low-density/very low-density lipoprotein were significantly increased following exposure to either MWCNTs. Plasma SAA3 levels correlated strongly with pulmonary Saa3 levels. Analysis of global gene expression revealed perturbation of the same biological processes and pathways in liver, including the HMG-CoA reductase pathway. Both MWCNTs induced similar histological hepatic changes, with a tendency towards greater response following CNTLarge exposure. Overall, we show that pulmonary exposure to two different MWCNTs induces similar systemic and hepatic responses, including changes in plasma APR, lipid composition, hepatic gene expression and liver morphology. The results link pulmonary exposure to MWCNTs with risk of cardiovascular disease.
Copyright © 2015. Published by Elsevier Inc.

Entities:  

Keywords:  Acute phase response; Atherosclerosis; Histology; Liver; Nanotoxicology; Toxicogenomics

Mesh:

Substances:

Year:  2015        PMID: 25620056     DOI: 10.1016/j.taap.2015.01.011

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  20 in total

1.  Fibrosis biomarkers in workers exposed to MWCNTs.

Authors:  Liliya M Fatkhutdinova; Timur O Khaliullin; Olga L Vasil'yeva; Ramil R Zalyalov; Ilshat G Mustafin; Elena R Kisin; M Eileen Birch; Naveena Yanamala; Anna A Shvedova
Journal:  Toxicol Appl Pharmacol       Date:  2016-02-20       Impact factor: 4.219

2.  Manually curated transcriptomics data collection for toxicogenomic assessment of engineered nanomaterials.

Authors:  Laura Aliisa Saarimäki; Antonio Federico; Iseult Lynch; Anastasios G Papadiamantis; Andreas Tsoumanis; Georgia Melagraki; Antreas Afantitis; Angela Serra; Dario Greco
Journal:  Sci Data       Date:  2021-02-08       Impact factor: 6.444

Review 3.  Understanding Nanomaterial-Liver Interactions to Facilitate the Development of Safer Nanoapplications.

Authors:  Jiulong Li; Chunying Chen; Tian Xia
Journal:  Adv Mater       Date:  2022-02-03       Impact factor: 32.086

4.  Investigating the bioavailability of graphene quantum dots in lung tissues via Fourier transform infrared spectroscopy.

Authors:  Tanveer A Tabish; Liangxu Lin; Muhammad Ali; Farhat Jabeen; Muhammad Ali; Rehana Iqbal; David W Horsell; Paul G Winyard; Shaowei Zhang
Journal:  Interface Focus       Date:  2018-04-20       Impact factor: 3.906

5.  Epoxy composite dusts with and without carbon nanotubes cause similar pulmonary responses, but differences in liver histology in mice following pulmonary deposition.

Authors:  Anne Thoustrup Saber; Alicja Mortensen; Józef Szarek; Ismo Kalevi Koponen; Marcus Levin; Nicklas Raun Jacobsen; Maria Elena Pozzebon; Stefano Pozzi Mucelli; David George Rickerby; Kirsten Kling; Rambabu Atluri; Anne Mette Madsen; Petra Jackson; Zdenka Orabi Kyjovska; Ulla Vogel; Keld Alstrup Jensen; Håkan Wallin
Journal:  Part Fibre Toxicol       Date:  2016-06-29       Impact factor: 9.400

6.  Multi-walled carbon nanotube-physicochemical properties predict the systemic acute phase response following pulmonary exposure in mice.

Authors:  Sarah S Poulsen; Kristina B Knudsen; Petra Jackson; Ingrid E K Weydahl; Anne T Saber; Håkan Wallin; Ulla Vogel
Journal:  PLoS One       Date:  2017-04-05       Impact factor: 3.240

7.  Primary genotoxicity in the liver following pulmonary exposure to carbon black nanoparticles in mice.

Authors:  Justyna Modrzynska; Trine Berthing; Gitte Ravn-Haren; Nicklas Raun Jacobsen; Ingrid Konow Weydahl; Katrin Loeschner; Alicja Mortensen; Anne Thoustrup Saber; Ulla Vogel
Journal:  Part Fibre Toxicol       Date:  2018-01-03       Impact factor: 9.400

8.  Editorial: dose-dependent ZnO particle-induced acute phase response in humans warrants re-evaluation of occupational exposure limits for metal oxides.

Authors:  Ulla Vogel; Flemming R Cassee
Journal:  Part Fibre Toxicol       Date:  2018-02-12       Impact factor: 9.400

9.  2-amino-1-methyl-6-phenylimidazo(4,5-b) pyridine (PhIP) induces gene expression changes in JAK/STAT and MAPK pathways related to inflammation, diabetes and cancer.

Authors:  Lora J Rogers; Alexei G Basnakian; Mohammed S Orloff; Baitang Ning; Aiwei Yao-Borengasser; Vinay Raj; Susan Kadlubar
Journal:  Nutr Metab (Lond)       Date:  2016-08-20       Impact factor: 4.169

10.  Surface modification does not influence the genotoxic and inflammatory effects of TiO2 nanoparticles after pulmonary exposure by instillation in mice.

Authors:  Håkan Wallin; Zdenka O Kyjovska; Sarah S Poulsen; Nicklas R Jacobsen; Anne T Saber; Stefan Bengtson; Petra Jackson; Ulla Vogel
Journal:  Mutagenesis       Date:  2016-09-22       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.